Table 3.
Univariate analysis of DFS and OS according to clinicopathological variables
| Variables | DFS | OS | |||
|---|---|---|---|---|---|
| χ 2 | P-value | χ 2 | P-value | ||
| Age (years) | ≤50 vs. >50 | 0.058 | 0.810 | 0.436 | 0.509 |
| Tumor size (cm)a | ≤2 vs. >2, ≤5 vs. >5 | 2.515 | 0.284 | 2.608 | 0.271 |
| Lymph node stage | negative vs. positive | 11.706 | 0.001 | 8.803 | 0.003 |
| Grade | G1 vs. G2 vs. G3 | 4.764 | 0.092 | 3.204 | 0.201 |
| Clinical stagea | I vs. II vs. III and IV | 10.343 | 0.006 | 8.576 | 0.014 |
| Histological type | IDC vs. ILC vs. Others | 0.588 | 0.745 | 0.883 | 0.643 |
| Ki-67 LI | Low (≤14 %) vs. High (>14 %) | 1.974 | 0.160 | 2.709 | 0.100 |
| Chemotherapy | AC vs. AC-T vs. Others vs. None | 0.664 | 0.882 | 1.194 | 0.754 |
| Radiotherapy | No vs. Yes | 0.091 | 0.763 | 0.002 | 0.963 |
| PELP1 status | Low vs. High | 2.887 | 0.089 | 3.182 | 0.074 |
Abbreviations: LN, lymph node; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Ki-67 LI, Ki-67 label index; AC, Adriamycin/Cyclophosphamide; AC-T, Adriamycin/Cyclophosphamide-Taxol; DFS, disease-free survival; OS, overall survival
Note: afor the variable, data for two cases are unavailable from medical records